Are Mangalam Drugs latest results good or bad?

Mangalam Drugs and Organics has reported its financial results for the quarter ending June 2025, revealing several concerning trends in its performance metrics. The net sales for this quarter were recorded at Rs 57.35 crore, which reflects a significant decline of 27.9% compared to the average of Rs 79.56 crore over the previous four quarters. This decline in sales is indicative of challenges in maintaining revenue levels.
The profit before tax (PBT), adjusted for other income, fell to Rs -13.00 crore, marking a substantial decline from the average PBT of Rs 1.07 crore in prior quarters. This represents the lowest PBT recorded in the last five quarters, highlighting a significant operational setback for the company.

Furthermore, the operating profit margin dropped to -7.79%, suggesting a deterioration in operational efficiency. The earnings per share (EPS) also reached a low of Rs -8.72, reflecting a decline in profitability and lower returns for shareholders.

In terms of quarterly comparisons, the net sales showed a QoQ growth of -21.39% compared to -17.81% in the previous quarter, indicating a continued downward trend. The standalone net profit also exhibited a drastic decline of -9,253.33% QoQ, further emphasizing the challenges faced by the company.

Overall, the financial indicators for Mangalam Drugs suggest a challenging period, with negative trends across multiple performance metrics. Additionally, the company saw an adjustment in its evaluation, reflecting the current operational difficulties it is encountering.